These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
895 related articles for article (PubMed ID: 8637045)
21. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600 [TBL] [Abstract][Full Text] [Related]
22. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334 [TBL] [Abstract][Full Text] [Related]
23. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359 [TBL] [Abstract][Full Text] [Related]
24. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990 [TBL] [Abstract][Full Text] [Related]
25. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer]. Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692 [TBL] [Abstract][Full Text] [Related]
26. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572 [TBL] [Abstract][Full Text] [Related]
27. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Letsch M; Schally AV; Busto R; Bajo AM; Varga JL Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852 [TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262 [TBL] [Abstract][Full Text] [Related]
29. Bone extracellular matrix induces homeobox proteins independent of androgens: possible mechanism for androgen-independent growth in human prostate cancer cells. Robbins SE; Shu WP; Kirschenbaum A; Levine AC; Miniati DN; Liu BC Prostate; 1996 Dec; 29(6):362-70. PubMed ID: 8977633 [TBL] [Abstract][Full Text] [Related]
30. Rap2 regulates androgen sensitivity in human prostate cancer cells. Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750 [TBL] [Abstract][Full Text] [Related]
31. Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. Donat SM; Powell CT; Israeli RS; Fair WR; Heston WD J Natl Cancer Inst; 1995 Jan; 87(1):41-6. PubMed ID: 7666462 [TBL] [Abstract][Full Text] [Related]
32. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546 [TBL] [Abstract][Full Text] [Related]
33. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice. Church D; Zhang Y; Rago R; Wilding G Cancer Chemother Pharmacol; 1999; 43(3):198-204. PubMed ID: 9923549 [TBL] [Abstract][Full Text] [Related]
35. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis. Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098 [TBL] [Abstract][Full Text] [Related]
36. Human prostate cancer progression models and therapeutic intervention. Chung LW; Kao C; Sikes RA; Zhau HE Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028 [TBL] [Abstract][Full Text] [Related]
37. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Gleave M; Hsieh JT; Gao CA; von Eschenbach AC; Chung LW Cancer Res; 1991 Jul; 51(14):3753-61. PubMed ID: 1712249 [TBL] [Abstract][Full Text] [Related]
38. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J J Androl; 2003; 24(5):681-7. PubMed ID: 12954658 [TBL] [Abstract][Full Text] [Related]
39. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Umekita Y; Hiipakka RA; Kokontis JM; Liao S Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11802-7. PubMed ID: 8876218 [TBL] [Abstract][Full Text] [Related]